Product Information
FINZALA 1-0.02(24)-75 CHEW TAB is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.3041 per EA under NDC 00093821062. Its NADAC has been published 209 times since Oct 5, 2022.
FDA first approved this application on Apr 7, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
FINZALA 1-0.02(24)-75 CHEW TAB
norethindrone acetate and ethinyl estradiol and ferrous fumarateManufacturer
Teva Pharmaceuticals USA Inc.NDC
00093821062
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA210087FDA Approved
4/7/2020
TE Code
AB
On Market Since
8/4/2022
Price Statistics
The NADAC for FINZALA 1-0.02(24)-75 CHEW TAB has been published 209 times since Oct 5, 2022, and over the history we have for it it has risen 39.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3041 per EA |
|---|---|
| All-time high | $0.4407 (Jan 14, 2026) |
| All-time low | $0.1310 (Oct 18, 2023) |
| 52-week high | $0.4407 |
| 52-week low | $0.2203 |
| Median price | $0.2653 |
| Average price | $0.2708 |
| Largest weekly change | +89.1% (Nov 22, 2023) |
| Weeks tracked | 209 |
| Tracking since | Oct 5, 2022 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 58% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norethindrone acetate and ethinyl estradiol and ferrous fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FINZALA 1-0.02(24)-75 CHEW TAB?
The current National Average Drug Acquisition Cost (NADAC) for FINZALA 1-0.02(24)-75 CHEW TAB, manufactured by Teva Pharmaceuticals USA Inc., is $0.3041 per EA (NDC 00093821062), effective Sep 30, 2026.
How has the price of FINZALA 1-0.02(24)-75 CHEW TAB changed over time?
Over the history we have for it, the NADAC for FINZALA 1-0.02(24)-75 CHEW TAB has risen 39.6%. It has been tracked across 209 weekly CMS publications since Oct 5, 2022.
What are the highest and lowest recorded NADAC prices for FINZALA 1-0.02(24)-75 CHEW TAB?
Since Oct 5, 2022, the NADAC for FINZALA 1-0.02(24)-75 CHEW TAB has ranged from a low of $0.1310 (Oct 18, 2023) to a high of $0.4407 (Jan 14, 2026), with a median of $0.2653 per EA.
Are there cheaper alternatives to FINZALA 1-0.02(24)-75 CHEW TAB?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, HAILEY FE 1-20 TABLET, is $0.1287 per EA — about 58% below FINZALA 1-0.02(24)-75 CHEW TAB.
Who manufactures FINZALA 1-0.02(24)-75 CHEW TAB?
FINZALA 1-0.02(24)-75 CHEW TAB (NDC 00093821062) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.